Characterization of androgen-regulated expression of CYP3A5 in human prostate

Carcinogenesis

Volumn 28, Issue 5, 2007, Pages 916-921

  Moilanen, Anne Mari ^a   Hakkola, Jukka ^a   Vaarala, Markku H ^a   Kauppila, Saila ^a   Hirvikoski, Pasi ^a   Vuoristo, Jussi T ^a   Edwards, Robert J ^b   Paavonen, Timo K ^c  

^a UNIVERSITY OF OULU   (Finland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYTOCHROME P450 3A5; MESSENGER RNA; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; BLADDER NECK STENOSIS; CANCER CELL CULTURE; CASTRATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; EPITHELIUM CELL; FEEDBACK SYSTEM; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSURETHRAL RESECTION; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATE; PROSTATE TUMOR; PROTEIN MICROARRAY; TUMOR CELL LINE;

ANDROGENS; CELL LINE; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; HUMANS; IN SITU HYBRIDIZATION; MALE; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; RECEPTORS, ANDROGEN; RESPONSE ELEMENTS; RNA, MESSENGER;

EID: 34447107070     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl222     Document Type: Article

References (39)

1. Gelmann, E.P. (2002) Molecular biology of the androgen receptor. J. Clin. Oncol., 20, 3001-3015.
2. Heinlein, C.A. et al. (2002) Androgen receptor (AR) coregulators: an over-view. Endocr. Rev., 23, 175-200.
3. Nelson, D.R. et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1-18.
4. Finta, C. et al. (2000) The human cytochrome P450 3A Iocus. Gene evolution by capture of downstream exons. Gene, 260, 13-23.
5. Kuehl, P. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetics basis of polymorphic CYP3A5 expression. Nat. Genet., 27, 383-391.
6. Wrighton, S.A. et al. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38, 207-213.
7. Anttila, S. et al. (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am. J. Respir. Cell Mol. Biol., 16 242-249.
8. Koch, I. et al. (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab. Dispos., 30, 1108-1114.
9. Yamakoshi, Y. et al. (1999) Human prostate CYP3AS: Identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem. Biophys. Res. Commun., 260, 676-681.
10. Burk, O. et al. (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem., 279, 38379-38385.
11. Hustert, E. et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11, 773-779.
12. Cooke, P.S. et al. (1991) Androgen receptor expression in developing male reproductive organs. Endocrinology, 128, 2867-2873.
13. Zeigler-Johnson, C. et al. (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res., 64, 8461-8467.
14. Hukkanen, J. et al. (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J. Pharmacol. Exp. Ther., 304; 745-752.
15. Sundin, M. et al. (1987) Isolation and catalyctic activity of cytochrome P-450 from ventral prostate of control rats. J. Biol. Chem. 262, 12293-12297.
16. Stromstedt, M. et al. (1990) Cloning and characterization of a novel member of the cytochrome P450 subfamily IVA in rat prostate. DNA Cell Biol., 9, 569-577.
17. Hukkanen, J. et al. (2002) Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol., 32, 391-411.
18. Majalahti-Palvianen, T. et al. (2000) Gene structure of a new cardiac peptide hormone: A model for heart-specific gene expression. Endocrinology, 141, 731-740.
19. Hakkola, J. et al. (2001) Cytochrome P450 3A expression in the human fetal liver: Evidence that CYP3A5 is expressed in only a limited number of fetal livers. Biol. Neonate 80, 193-201.
20. Edwards, RJ. et al. (1998) Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome. P450 in humans. Biochem. Pharmacol. 56, 377-387.
21. Vaarala, M.H. et al. (2001) The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: Detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer., 94, 705-710.
22. Resnick, R.M. et al. (1990) Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J. Natl Cancer Inst., 82 1477-1484.
23. Henttu, P. et al. (1992) Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology, 130, 766-772.
24. Reid, KJ. et al. (2001) Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J. Biol. Chem. 276, 2943-2952.
25. Burk, O. et al. (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol., 369, 105-124.
26. Finnstrom, N. et al. (2001) Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur. J. Clin. Invest., 31, 880-886.
27. Nishimura, M. et al. (2004) Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet., 19, 135-149.
28. Murray, G.I. et al. (1995) The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J. Pathol., 177 147-152.
29. Zhang, W. et al. (2006) Expression of drug pathway proteins is independent of tumour type. J. Pathol., 209, 213-219.
30. Aumuller, G. et al. (1990) Protein secretion and secretory processes in male accessory sex glands. Int. Rev. Cytol., 121 127-231.
31. Montironi, R. et al. (1994) Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J. Clin. Pathol., 47, 906-913.
32. Brolin, J. et al. (1992) Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate, 20, 281-295.
33. Lee, C. (1996) Role of androgen in prostate growth and regression: stromal-epithelial interaction. Prostate Suppl., 6, 52-56.
34. Gao, J. et al. (2001) Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res., 61, 5038-5044.
35. Brown, T.R. et al. (1976) Androgen receptor dependent and independent activities of testosterone on hepatic microsomal drug metabolism. Endocrinology, 99, 1353-1362.
36. Sunahara, G.I. et al. (1987) Effect of flutamide on hepatic cytosolic methyltrienolone (R1881) binding kinetics and testosterone responsive hepatic drug and steroid metabolism in the adult male rat. Biochem Pharmacol., 36, 3571-3577.
37. Nebert, D.W. (1994) Drug-metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol., 47, 25-37.
38. Fleming, I. (2001) Cytochrome p450 and vascular homeostasis. Circ. Res., 89, 753-762.
39. Aoyama, T. et al. (1989) Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specifities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem., 264, 10388-10395.